Galmed Pharmaceuticals Ltd (GLMD)

NASDAQ
2.610
-0.140(-5.09%)
  • Volume:
    83,136
  • Bid/Ask:
    2.500/2.630
  • Day's Range:
    2.550 - 2.755

GLMD Overview

Prev. Close
2.75
Day's Range
2.55-2.755
Revenue
-
Open
2.755
52 wk Range
2.15-6.22
EPS
-1.44
Volume
83,136
Market Cap
65.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
104,026
P/E Ratio
-
Beta
2.21
1-Year Change
-42.26%
Shares Outstanding
25,083,914
Next Earnings Date
Nov 08, 2021
What is your sentiment on Galmed Pharmaceuticals Ltd?
or
Market is currently closed. Voting is open during market hours.

Galmed Pharmaceuticals Ltd News

Galmed Pharmaceuticals Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsStrong BuySellStrong SellStrong SellStrong Sell
SummaryBuySellStrong SellStrong SellStrong Sell

Galmed Pharmaceuticals Ltd Company Profile

Galmed Pharmaceuticals Ltd Company Profile

Employees
21

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Read More
  • Why the drop? Do they have anything in the pipeline?
    1
    • They have
      0
  • will it go up soon or back down first?
    0
    • Who knows?
      0
  • I love glmd stock and its people.theres a real very real vision hiding there and yields too. .
    0
    • Glmd is like a little green plant.give it strength so it can stand up and walks by its own!!
      0
      • I believe glmd and despise those who trhow the stock panickly...
        0
        • I believe in glmd because it has a vision. Seeking alfa critisized it vicously and twisted wrongly the wonderfull results of the trial of armacholl. I salute to the wonderfull pannel of ceo and directors of glmd.
          0
          • ITS MUCH BETTER IF HE HAD BOUGHT MISERABE TEVA....
            0
            • please mr FROST-STOP MANIPULATE OPK STOCK!
              0
              • ITS A PITY THEY LET MR FROST MANIPULATE OPK STOCK. IN MY VIEW ITS UNETHICHAL AND ON THE SIDELINES OF A CRIMINAL OFFENCE.r. r. MR FROST-DONT MANIPULATE OUR STOCK MARKET. WE DONT NEED YOU!
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.